Abstract
We examined the role of autoantibodies to β2-GPI and prothrombin (PT) in the inhibition of annexin V binding to cardiolipin (CL) and the association with clinical manifestations of the anti-phospholipid syndrome (APS). Plasma samples from 59 patients with anti-phospholipid (aPL) antibodies were studied. Affinity purification of total IgG and IgG anti-ß2-GPI antibodies was performed using staphylococcal protein A and phospholipid liposomes. Annexin V binding to CL was significantly inhibited by 31/59 (53%) aPL+ plasma samples. There was a significant association between annexin V inhibition and elevated levels of IgG anti-cardiolipin (aCL) (r = −0·62; P < 0·001), IgG anti-ß2-GPI (r = −0·67; P < 0·001) and a weaker association with lupus anti-coagulant (r = −0·27; P = 0·05). There was no association with other isotypes of aCL and anti-ß2-GPI or with anti-PT of any isotype. In patients with clinical manifestations of the APS there were higher levels of IgG aCL (median (range) Z score): 10·0 (0–17·6) versus 5·0 (0–16·1); P = 0·03), IgG anti-ß2-GPI (4·5 (0–11·3) versus 0·9 (0–9·7); P = 0·02) and greater inhibition of annexin V binding to CL (−3·4 (−11·4–0·6) versus−1·1 (−10·8–1·2); P = 0·22). Odds ratios for the laboratory assays and the presence of clinical manifestations of the APS varied between 0·38 and 4·16, with the highest values for IgG aCL (4·16), IgG anti-ß2-GPI (3·28) and annexin V inhibition (2·85). Additional experiments with affinity-purified IgG antibodies indicated that inhibition of annexin V binding was dependent upon the concentration of ß2-GPI and anti-ß2-GPI antibodies. These results indicate that inhibition of annexin V binding to procoagulant phospholipid surfaces is dependent upon anti-ß2-GPI antibodies and suggest a role for annexin V in the pathogenesis of the APS.

This publication has 40 references indexed in Scilit: